327 related articles for article (PubMed ID: 36142332)
21. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
[TBL] [Abstract][Full Text] [Related]
22. Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.
Pott J; Gådin JR; Theusch E; Kleber ME; Delgado GE; Kirsten H; Hauck SM; Burkhardt R; Scharnagl H; Krauss RM; Loeffler M; März W; Thiery J; Silveira A; Van't Hooft FM; Scholz M
Hum Mol Genet; 2022 Mar; 31(6):999-1011. PubMed ID: 34590679
[TBL] [Abstract][Full Text] [Related]
23. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
24. Association between genetically proxied PCSK9 inhibition and systemic lupus erythematosus risk: A mendelian randomization study.
Ji X; Guo HY; Han M; Peng H; Yuan H
Int J Rheum Dis; 2024 Apr; 27(4):e15106. PubMed ID: 38568054
[TBL] [Abstract][Full Text] [Related]
25. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians.
Tsai CW; North KE; Tin A; Haack K; Franceschini N; Saroja Voruganti V; Laston S; Zhang Y; Best LG; MacCluer JW; Beaty TH; Navas-Acien A; Kao WH; Howard BV
J Clin Endocrinol Metab; 2015 Feb; 100(2):E345-9. PubMed ID: 25412415
[TBL] [Abstract][Full Text] [Related]
26. PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.
Holmes MV; Kartsonaki C; Boxall R; Lin K; Reeve N; Yu C; Lv J; Bennett DA; Hill MR; Yang L; Chen Y; Du H; Turnbull I; Collins R; Clarke RJ; Tobin MD; Li L; Millwood IY; Chen Z; Walters RG;
Eur J Prev Cardiol; 2024 Jun; 31(8):1015-1025. PubMed ID: 38198221
[TBL] [Abstract][Full Text] [Related]
27. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.
Harrison SC; Holmes MV; Burgess S; Asselbergs FW; Jones GT; Baas AF; van 't Hof FN; de Bakker PIW; Blankensteijn JD; Powell JT; Saratzis A; de Borst GJ; Swerdlow DI; van der Graaf Y; van Rij AM; Carey DJ; Elmore JR; Tromp G; Kuivaniemi H; Sayers RD; Samani NJ; Bown MJ; Humphries SE
JAMA Cardiol; 2018 Jan; 3(1):26-33. PubMed ID: 29188294
[TBL] [Abstract][Full Text] [Related]
28. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
He JY; Zhang X; Wang K; Lv WQ
J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
[TBL] [Abstract][Full Text] [Related]
29. Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.
Lee CJ; Lee Y; Park S; Kang SM; Jang Y; Lee JH; Lee SH
PLoS One; 2017; 12(10):e0186446. PubMed ID: 29036232
[TBL] [Abstract][Full Text] [Related]
30. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
31. Low LDL cholesterol,
Benn M; Nordestgaard BG; Frikke-Schmidt R; Tybjærg-Hansen A
BMJ; 2017 Apr; 357():j1648. PubMed ID: 28438747
[No Abstract] [Full Text] [Related]
32. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
33. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
Hopewell JC; Malik R; Valdés-Márquez E; Worrall BB; Collins R;
Eur Heart J; 2018 Feb; 39(5):354-359. PubMed ID: 29020353
[TBL] [Abstract][Full Text] [Related]
35. Low-density lipoprotein cholesterol and lifespan: A Mendelian randomization study.
Daghlas I; Gill D
Br J Clin Pharmacol; 2021 Oct; 87(10):3916-3924. PubMed ID: 33704808
[TBL] [Abstract][Full Text] [Related]
36. Association of genetically predicted lipid traits and lipid-modifying targets with heart failure.
Xiao J; Ji J; Zhang N; Yang X; Chen K; Chen L; Huang W
Eur J Prev Cardiol; 2023 Mar; 30(4):358-366. PubMed ID: 36520639
[TBL] [Abstract][Full Text] [Related]
37. Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug-Target Mendelian Randomization Study.
Bell AS; Rosoff DB; Mavromatis LA; Jung J; Wagner J; Lohoff FW
J Am Heart Assoc; 2022 Nov; 11(21):e026122. PubMed ID: 36285785
[TBL] [Abstract][Full Text] [Related]
38. Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study.
Tao H; Yu Z; Dong Y; Liu L; Peng L; Chen X
Front Immunol; 2023; 14():1160312. PubMed ID: 37350960
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.
Miyake Y; Kimura R; Kokubo Y; Okayama A; Tomoike H; Yamamura T; Miyata T
Atherosclerosis; 2008 Jan; 196(1):29-36. PubMed ID: 17316651
[TBL] [Abstract][Full Text] [Related]
40. Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus: dual evidence from NHANES database and Mendelian randomization analysis.
Yan Z; Xu Y; Li K; Liu L
Front Endocrinol (Lausanne); 2024; 15():1272314. PubMed ID: 38455653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
